Scientific article

Residual risk of liver disease after hepatitis C virus eradication

ContributorsNegro, Francesco
Published inJournal of Hepatology, vol. 74, no. 4, p. 952-963
Publication date2021

Treatment of hepatitis C with direct-acting antivirals is safe and highly efficacious, resulting in viral clearance (sustained virological response [SVR]) in the vast majority of patients. Although SVR is mostly permanent and associated with a significant reduction of liver morbidity and mortality, some patients may still suffer from a major risk of progressive liver damage, potentially leading to severe complications - including liver decompensation, hepatocellular carcinoma and death. This concise review discusses some of the most important features of residual liver disease in patients with chronic hepatitis C who have achieved SVR after antiviral therapy.

  • Liver-relatedmortality
  • Cirrhosis
  • Hepatocellular carcinoma
  • Steatosis
  • Antivirals
Citation (ISO format)
NEGRO, Francesco. Residual risk of liver disease after hepatitis C virus eradication. In: Journal of Hepatology, 2021, vol. 74, n° 4, p. 952–963. doi: 10.1016/j.jhep.2020.11.040
Main files (1)
Article (Published version)
ISSN of the journal0168-8278

Technical informations

Creation06/17/2021 2:02:00 PM
First validation06/17/2021 2:02:00 PM
Update time03/16/2023 12:48:40 AM
Status update03/16/2023 12:48:39 AM
Last indexation01/17/2024 1:34:42 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack